Navigation Links
Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
Date:10/5/2007

SOUTH SAN FRANCISCO, Calif., Oct. 5 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., today announced Paul Sekhri, Cerimon's President and Chief Executive Officer, will present at the 2007 BIO Investor Forum on Thursday, October 11, 2007, at 9:30 a.m. PDT at the Palace Hotel in San Francisco. The presentation will take place in the Pacific Heights room.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new treatment options will enable physicians specialized in treating these conditions to further improve the lives of their patients.

Cerimon currently has two drugs in development. Simulect(R) (basiliximab)entered a Phase IIb study for moderate-to-severe steroid-refractory ulcerative colitis in the first quarter of 2007, and the Company has initiated a Phase I study of a topical patch formulation of diclofenac sodium. This study will rapidly be followed by late-stage efficacy and safety studies in patients with acute musculoskeletal pain.

Cerimon is well financed, having closed a $70 million Series A financing in late 2005 with the premier investors MPM, Nomura Phase4 Ventures, and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com/.


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, ... to help treat hormonal and stress related hair loss. With patent-pending formulas for ... of key opinion leaders in the medical and salon channels nationwide. , ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... talent development, skill-building and compliance training platform on mobile devices, today released a ... of Regulatory Requirements for Medical Devices. The course is essential for owners or ...
(Date:5/3/2016)... ... 03, 2016 , ... Leading CEOs from biotech, pharmaceutical, and ... June 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference ... exclusive access to key decision makers who influence deal making and investment. Attendees ...
(Date:5/3/2016)... ... May 03, 2016 , ... Kerafast ... bioresearch materials from laboratories across the globe, today announced the availability of a ... pace of research toward treatment and prevention measures for the Zika virus, the ...
Breaking Biology Technology:
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):